Martín Demichelis has just been announced, on Thursday afternoon, as the new coach of RCD Mallorca. Following the dismissal of Jagoba Arrasate, the Argentine coach has signed until the end of the ...

Throughout the year, Teva had momentum in innovative medicines, scaling its global generics and biosimilars portfolio. On the brand side, Teva said it continued to showcase strong performance of its ...

We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical ...

Teva Pharmaceutical Industries (TEVA) shares snapped six straight sessions of gains, as the stock closed 0.4% lower at $33.07 on Thursday. The generic drugmaker gained about 6% in the preceding six ...

Teva President and CEO Richard Francis joins 'Mad Money' host Jim Cramer to talk quarterly results, its growth strategy, changed in FDA development pipeline, and more. Got a confidential news tip? We ...

Teva Pharmaceutical is one of the leading global generic drug manufacturers. By our estimate, roughly 70% of its total revenue is derived from generics and off-patent branded drugs. Generic drugs in ...

One year after Forte married his wife Olivia Modling, her brother Doug was diagnosed with HD. Around 41,000 Americans live with the disease according to the Huntington’s Disease Society of America, ...

A Georgia federal judge on Monday reportedly denied Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) a request to delay the first trial in thousands of lawsuits alleging its Paragard intrauterine ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development of a drug for vitiligo. The deal centers around TEV-‘408, an anti-IL-15 ...

Both agencies highlighted Teva's financial discipline, solid liquidity, and return to revenue growth after five years of declines, driven by strength in branded medicines and stabilization in generics ...

Teva, the Israeli pharmaceutical giant, is reaching new heights, breaking the $30 mark. The rise in its share price reflects both the strengthening of its balance sheet and the rising sales of Austedo ...

A new mental health-driven biotech has arrived in Syremis Therapeutics. Co-founded by the mind behind Karuna Therapeutics and its novel schizophrenia treatment Cobenfy, the company has officially ...